Arrowhead Pharmaceuticals Valuation
| ARWR Stock | USD 18.54 0.26 1.42% |
At this time, the firm appears to be undervalued. Arrowhead Pharmaceuticals shows a prevailing Real Value of $28.1 per share. The current price of the firm is $18.54. Our model approximates the value of Arrowhead Pharmaceuticals from analyzing the firm fundamentals such as Operating Margin of (27.85) %, return on equity of -1.52, and Shares Outstanding of 124.31 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Arrowhead Pharmaceuticals' valuation include:
Price Book 6.9727 | Enterprise Value 2 B | Enterprise Value Ebitda (11.02) | Price Sales 117.3046 | Forward PE 111.1111 |
Undervalued
Today
Please note that Arrowhead Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Arrowhead Pharmaceuticals is based on 3 months time horizon. Increasing Arrowhead Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Arrowhead stock is determined by what a typical buyer is willing to pay for full or partial control of Arrowhead Pharmaceuticals. Since Arrowhead Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Arrowhead Stock. However, Arrowhead Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 18.54 | Real 28.1 | Target 55.57 | Hype 18.84 | Naive 17.01 |
The intrinsic value of Arrowhead Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Arrowhead Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Arrowhead Pharmaceuticals helps investors to forecast how Arrowhead stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arrowhead Pharmaceuticals more accurately as focusing exclusively on Arrowhead Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Arrowhead Pharmaceuticals' intrinsic value based on its ongoing forecasts of Arrowhead Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Arrowhead Pharmaceuticals' closest peers.
Arrowhead Pharmaceuticals Cash |
|
Arrowhead Valuation Trend
Arrowhead Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of Arrowhead Pharmaceuticals' financial worth over time. Using both Arrowhead Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Arrowhead Pharmaceuticals Total Value Analysis
Arrowhead Pharmaceuticals is presently anticipated to have valuation of 1.99 B with market capitalization of 2.3 B, debt of 115.17 M, and cash on hands of 416.5 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Arrowhead Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.99 B | 2.3 B | 115.17 M | 416.5 M |
Arrowhead Pharmaceuticals Investor Information
About 80.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings (P/E) ratio of 482.39. Arrowhead Pharmaceuticals recorded a loss per share of 4.65. The entity last dividend was issued on the 29th of October 2010. The firm had 1:10 split on the 17th of November 2011. Based on the key indicators related to Arrowhead Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Arrowhead Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Arrowhead Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Arrowhead Pharmaceuticals has an asset utilization ratio of 31.45 percent. This connotes that the Company is making $0.31 for each dollar of assets. An increasing asset utilization means that Arrowhead Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Arrowhead Pharmaceuticals Ownership Allocation
Arrowhead Pharmaceuticals holds a total of 124.31 Million outstanding shares. The majority of Arrowhead Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Arrowhead Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Arrowhead Pharmaceuticals. Please pay attention to any change in the institutional holdings of Arrowhead Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Arrowhead Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 240.74 M. Net Loss for the year was (209.28 M) with profit before overhead, payroll, taxes, and interest of 240.74 M.About Arrowhead Pharmaceuticals Valuation
The stock valuation mechanism determines Arrowhead Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Arrowhead Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Arrowhead Pharmaceuticals. We calculate exposure to Arrowhead Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Arrowhead Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 276.8 M | 290.7 M | |
| Pretax Profit Margin | (0.99) | (1.04) | |
| Operating Profit Margin | (0.98) | (1.03) | |
| Net Loss | (0.98) | (1.03) | |
| Gross Profit Margin | 0.86 | 0.54 |
Arrowhead Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Arrowhead Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 106.8 M | |
| Quarterly Earnings Growth Y O Y | 0.098 | |
| Forward Price Earnings | 111.1111 |
Arrowhead Pharmaceuticals Current Valuation Indicators
Arrowhead Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Arrowhead Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Arrowhead Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Arrowhead Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Arrowhead Pharmaceuticals' worth.Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.